TRIM32 and neoplasm: Former research by Wu et al. analyzed the expression, mutations, and prognosis of 13 tumor stem cell associated TRIM genes (TRIM6, TRIM8, TRIM11, TRIM14, TRIM16, PML, TRIM21, TRIM24, TRIM25, TRIM27, TRIM28, TRIM32, and TRIM71) in KIRC, and they utilized these TRIM genes to construct a risk model and confirmed its prediction performance in internal but not in external KIRC cohort (23).